AARTIDRUGS

March 7 (Reuters) - Aarti Drugs Ltd ADRG.NS:

• AARTI DRUGS LTD - RECEIVES ADMINISTRATIVE WARNING LETTER FROM SEBI

• AARTI DRUGS LTD - WARNING ISSUED FOR VIOLATION OF INSIDER TRADING REGULATIONS

Source text: ID:nBSE2bv5vK

Further company coverage: ADRG.NS

(([email protected];))

March 6 (Reuters) - Aarti Drugs Ltd ADRG.NS:

• AARTI DRUGS LTD - SEBI ISSUES ADMINISTRATIVE WARNING TO CO'S COMPLIANCE OFFICER, COMPANY SECRETARY

• AARTI DRUGS LTD - NO IMPACT ON FINANCIAL, OPERATIONAL OR OTHER ACTIVITIES

Source text: ID:nBSE1T64wJ

Further company coverage: ADRG.NS

(([email protected];))

** Shares of Aarti Drugs ADRG.NS jump 13% to 433 rupees, in a broader weak market

** US FDA lifts import restrictions imposed following inspection at co's active pharmaceutical ingredient (API) manufacturing facility

** Following the order, ADRG can now export its API products to the US

** Nifty Pharma Index .NIPHARM is down 3% on Trump tariff woes; ADRG is not part of the index

** ADRG trading vols at 3.5x their 30-day avg

** Stock is down around 13% YTD

(Reporitng by Nishit Navin)

(([email protected];))

Feb 3 (Reuters) - Aarti Drugs Ltd ADRG.NS:

• AARTI DRUGS LTD - TO ACQUIRE 26.25% EQUITY IN PRO-ZEAL GREEN POWER NINE

• AARTI DRUGS LTD - TOTAL ACQUISITION COST 80.5 MILLION RUPEES

Source text: ID:nBSE43b8YN

Further company coverage: ADRG.NS

(([email protected];;))

Jan 29 (Reuters) - Aarti Drugs Ltd ADRG.NS:

• AARTI DRUGS DEC-QUARTER CONSOL NET PROFIT 370.5 MILLION RUPEES

• AARTI DRUGS DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 5.57 BILLION RUPEES

Source text: [ID:]

Further company coverage: ADRG.NS

(([email protected];))

** Shares of Aarti Drugs ADRG.NS fall 2.7% to 471.60 rupees

** The pharmaceutical company reported a 12% dip Y/Y in Q2 consol profit, revenue falls 7% Y/Y

** Relative strength index falls to 20.2, suggesting that the stock might be oversold - LSEG data

** ADRG falls for 13th straight session

** Stock down ~4% YTD

(Reporting by Vijay Malkar)

(([email protected];))

** Shares of drugmaker Aarti Drugs ADRG.NS rise 2% to 525 rupees

** Co said UK's Medicines and Healthcare products Regulatory Agency issued GMP compliance certificate for unit's manufacturing facility in Himachal Pradesh

** Stock set to snap four straight weeks of losses, gained ~2% this week

** Stock has risen 7.7% YTD

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

Oct 3 (Reuters) - Aarti Drugs Ltd ADRG.NS:

• RECEIPT OF GMP CERTIFICATE FROM UK-MHRA FOR MANUFACTURING FACILITY OF UNIT

Source text for Eikon: ID:nBSE8NWNnW

Further company coverage: ADRG.NS

(([email protected];;))

** Shares of Aarti Drugs ADRG.NS fall as much as 2% to 510.20 rupees

** Drugmaker says its API manufacturing facility at Tarapur in Maharashtra, has received seven inspectional observations in Form 483 from the U.S. FDA

** A Form 483 is a type of agency report containing observations that FDA inspectors deem to be objectionable

** Stock on track for a third consecutive session of loss

** Stock last down 1%, cutting YTD gains to 5.4%

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Sept 25 (Reuters) - Aarti Drugs Ltd ADRG.NS:

• RECEIVED 7 INSPECTIONAL OBSERVATIONS IN FORM 483 FROM US FDA

• US FDA INSPECTION WAS AT API MANUFACTURING FACILITY AT TARAPUR

Source text for Eikon: ID:nNSEHbm5S

Further company coverage: ADRG.NS

(([email protected];;))

** Shares of India's Aarti Drugs ADRG.NS jump as much as 10.7% to 625.11 rupees, its highest since July 25, 2023

** Drugmaker says its board approved buyback of shares worth up to 598.5 mln rupees ($7.13 mln)

** ADRG up after snapping a 4-day winning streak last session

** Including day's gain, stock has risen ~26% YTD

($1 = 83.9000 Indian rupees)

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

** Shares of India's Aarti Drugs ADRG.NS jump 8.2% to 577.7 rupees

** Drugmaker says its board will consider buyback of shares on Aug. 26

** ADRG on track for fourth straight session of gains

** Day's rise takes YTD gains to 17.5%

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

Aug 1 (Reuters) - Aarti Drugs Ltd ADRG.NS:

• US FDA CONDUCTED INSPECTION AT UNIT'S MANUFACTURING FACILITY AT BADDI

• PINNACLE IS IN RECEIPT OF ESTABLISHMENT INSPECTION REPORT

Source text for Eikon: ID:nNSEHby3R

Further company coverage: ADRG.NS

(([email protected];))

** Shares of Aarti Drugs ADRG.NS gain ~2% to 512.55 rupees

** Drugmaker said US FDA concluded inspection at ADRG's manufacturing facility in Himachal Pradesh

** ADRG received establishment inspection report after conclusion of inspection

** Stock up ~5% YTD, set for second straight annual gain

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

July 29 (Reuters) - Aarti Drugs Ltd ADRG.NS:

• US FDA EIR AT MANUFACTURING FACILITY OF UNIT AT BADDI, HIMACHAL PRADESH

• GETS EIR FROM USFDA CONCLUDING INSPECTION AS CLOSED

Source text for Eikon: ID:nNSE4XTgJD

Further company coverage: ADRG.NS

(([email protected];))

July 26 (Reuters) - Aarti Drugs Ltd ADRG.NS:

• AARTI DRUGS LTD JUNE-QUARTER CONSOL NET PROFIT 332.4 MILLION RUPEES

• AARTI DRUGS LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 5.55 BILLION RUPEES

Source text for Eikon: ID:nNSE60vWys

Further company coverage: ADRG.NS

(([email protected];))

July 17 (Reuters) - Aarti Drugs Ltd ADRG.NS:

• CO DIRECTED TO VOLUNTARILY STOP MANUFACTURING PARTICULAR PRODUCT AT MAHARASHTRA PLANT

Source text for Eikon: ID:nNSE3RMX01

Further company coverage: ADRG.NS

(([email protected];))

June 18 (Reuters) - Aarti Drugs Ltd ADRG.NS:

• AARTI DRUGS LTD - FIRE OCCURRED AT N-198 UNIT LOCATED AT TARAPUR, MAHARASHTRA

• AARTI DRUGS LTD- FIRE WAS BROUGHT UNDER CONTROL IMMEDIATELY

• AARTI DRUGS LTD- HOWEVER PRODUCTION OPERATION OF SAID UNIT HAS BEEN TEMPORARILY DISRUPTED

• AARTI DRUGS LTD - NO LOSS OF LIFE OR INJURIES REPORTED DUE TO FIRE

• AARTI DRUGS LTD - COMPANY PROJECTS NO MATERIAL IMPACT ON FINANCIALS AND OPERATIONS OF BUSINESS

• AARTI DRUGS LTD- UNIT HAS ADEQUATE INSURANCE COVERAGE

• AARTI DRUGS LTD - DIFFICULT TO ASSESS FINANCIAL IMPACT ON COMPANY PURSUANT TO INCIDENT

• AARTI DRUGS LTD - COMPANY PROJECTS NO MATERIAL IMPACT ON FINANCIALS AND OPERATIONS OF BUSINESS

Source text for Eikon: ID:nBSE80LMgJ

Further company coverage: ADRG.NS

(([email protected];))

May 3 (Reuters) - Aarti Drugs Ltd ADRG.NS:

• AARTI DRUGS MARCH-QUARTER CONSOL NET PROFIT 473.7 MILLION RUPEES VERSUS PROFIT 560.9 MILLION RUPEES

• AARTI DRUGS MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 6.2 BILLION RUPEES VERSUS 7.42 BILLION RUPEES

Source text for Eikon: ID:nBSE3PdjKR

Further company coverage: ADRG.NS

(([email protected];;))

April 23 (Reuters) - Aarti Drugs Ltd ADRG.NS:

• USFDA HAS INSPECTED FORMULATIONS MANUFACTURING FACILITY OF OUR SUBSIDIARY

• COMPANY HAS RECEIVED 5 INSPECTIONAL OBSERVATIONS IN FORM 483

• NONE OF OBSERVATIONS RECEIVED ARE RELATED TO DATA INTEGRITY

• THERE IS NO IMPACT ON FINANCIAL, OPERATION OR OTHER ACTIVITIES OF CO

Source text for Eikon: ID:nBSE4Tqs60

Further company coverage: ADRG.NS

(([email protected];))

** Shares of Aarti Drugs ADRG.NS rise 3.9% to 454.7 rupees; last up ~3.2%

** The Gujarat Pollution Control Board (GPCB) permanently revoked a closure order issued for co's Sarigam Plant, dated March 30, 2022

** The plant manufactures diabetes drug metformin hydrochloride; a trial revocation of the closure was issued on April 30, 2022

** Stock on track to snap two consecutive session of losses

** Still, stock eyes fourth consecutive week of losses

** Stock down nearly 7.6% YTD vs 9.9% rise in Nifty pharma index .NIPHARM

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

Jan 30 (Reuters) - Aarti Drugs Ltd ADRG.NS:

• INITIATING COMMERCIAL PRODUCTION OF DERMATOLOGY PRODUCT AT FACILITY IN TARAPUR, MAHARASHTRA

• TOTAL INVESTMENT REQUIREMENT 1.5-2 BILLION RUPEES

• FACILITY WILL HAVE TOTAL OPERATIONAL CAPACITY OF 24,000 MTPA

Source text for Eikon: ID:nBSE2h6p7B

Further company coverage: ADRG.NS

(([email protected];))

** Shares of Aarti Drugs ADRG.NS drop nearly 5% to 508.9 rupees

** ADRG's Dec-qtr profit and revenue from operations both down 14% y-o-y

** Says revenue from domestic market, 67% of total, declines ~4.5%

** If losses hold, stock on track to fall for six sessions out of 19 so far this month

** Stock up nearly 4% YTD vs 4.4% rise in Nifty pharma index .NIPHARM

(Reporting by Rama Venkat in Bengaluru)

(([email protected]; https://twitter.com/ramavenkat0607;))

Oct 19 (Reuters) - Aarti Drugs Ltd ADRG.NS:

• SEPT-QUARTER CONSOL NET PROFIT 395.9 MILLION RUPEES VERSUS 387.5 MILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 6.42 BILLION RUPEES VERSUS 6.88 BILLION RUPEES

(([email protected];))

** Shares of Aarti Drugs ADRG.NS rise as much as 19.1% to 607.9 rupees, highest level since Dec. 13, 2021

** Stock posts biggest intraday pct gain since March 20

** Pharmaceutical company's June-qtr consolidated net profit rises 37.5% to 478.5 mln rupees ($5.84 mln)

** Rev from ops rose 6.3% to 6.61 bln rupees

** Board approves buyback of shares worth upto 598.5 mln rupees at 900 rupees apiece

** More than 8.5 mln shares traded by 12:22 p.m. IST, 20.4x the 30-day avg

** As of last close, stock up nearly 11% YTD

($1 = 81.8860 Indian rupees)

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

July 21 (Reuters) - Aarti Drugs Ltd ADRG.NS:

• INDIA'S AARTI DRUGS JUNE-QUARTER CONSOL NET PROFIT 478.5 MILLION RUPEES VERSUS 347.9 MILLION RUPEES

• AARTI DRUGS JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 6.61 BILLION RUPEES VERSUS 6.22 BILLION RUPEES

• APPROVED BUYBACK OF SHARES WORTH UP TO 598.5 MILLION RUPEES

• APPROVED BUYBACK PRICE AT 900 RUPEES PER SHARE

Source text for Eikon: ID:nBSE7ryzNN

Further company coverage: ADRG.NS

(([email protected];;))

** Shares of Aarti Drugs ADRG.NS rise as much as 8.8% after co reported a 1.4% rise in Q4 net profit

** Revenue from APIs and specialty chemicals grew 10% and 56%; revenue from ops up 6.9%

** Stock crosses its 200-day exponential moving average; continues to stay above 50- and 100-day avgs

** Stock's MACD line above the signal line since April 5, indicating bullish momentum

** Stock posts its sharpest intraday pct gain since April 6

** More than ~1.1 mln shares change hands by 1:06 p.m. IST, 0.7x the 30-day avg

** Including session's gains, stock cuts YTD loss to 1.35% from 8.5% at last close

(Reporting by Dimpal Gulwani in Bengaluru)

(([email protected]))